Topics

Alembic Q2 Gets Sartans Shot

23:28 EDT 27 Oct 2019 | SCRIP

Continuing sartans crisis, new product launches in US help Alembic post strong Q2 performance despite slowdown in other markets.

      

Related Stories

 

Original Article: Alembic Q2 Gets Sartans Shot

NEXT ARTICLE

More From BioPortfolio on "Alembic Q2 Gets Sartans Shot"

Quick Search